ArticleIn vivo (Athens, Greece)
Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimAbemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, can cause severe liver injury, leading to treatment discontinuation. We report five cases of patients treated with a combined regimen of a CDK4/6 inhibitor and hormone therapy for metastatic breast cancer. Following the development of serious liver dysfunction (grade ≥3) during abemaciclib therapy, switching to palbociclib allowed continuation of CDK4/6 inhibitor treatment. CASE REPORT: The causative role of abemaciclib was assessed using the drug-induced liver injury scoring system (RECAM-J 2023), which evaluates multiple factors, including time to onset, course after onset, prior reports of liver injury, exclusion of other potential causes, and effects of re-administration. A score of ≥8 indicates a high likelihood of drug-induced liver injury; all five cases in this study met this criterion, with one case reaching a maximum score of 17. Because CDK4/6 inhibitors are administered alongside hormonal agents, we also evaluated the potential contribution of concomitant endocrine therapy. The likelihood of hormonal agents causing liver injury was assessed as "Possible." Each patient underwent further hepatological evaluation, including testing for viral hepatitis and autoimmune hepatitis. Based on these assessments, the hepatologist confirmed drug-induced liver injury. injury. Following normalization of liver function test values, patients were switched to palbociclib. No recurrence of liver dysfunction was observed, allowing CDK4/6 inhibitor therapy to continue successfully.
conclusionThese cases suggest that severe liver damage induced by abemaciclib, does not necessarily preclude continued CDK4/6 inhibitor therapy. Switching to palbociclib may be a feasible strategy, provided liver function has recovered before reinitiating treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.